A detailed history of Principal Financial Group Inc transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 1,238,476 shares of DNLI stock, worth $30.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,238,476
Previous 1,088,537 13.77%
Holding current value
$30.6 Million
Previous $25.3 Million 42.73%
% of portfolio
0.02%
Previous 0.02%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

BUY
$20.96 - $31.05 $3.14 Million - $4.66 Million
149,939 Added 13.77%
1,238,476 $36.1 Million
Q2 2024

Jul 29, 2024

SELL
$14.96 - $23.22 $508,625 - $789,456
-33,999 Reduced 3.03%
1,088,537 $25.3 Million
Q1 2024

Apr 29, 2024

BUY
$15.83 - $23.35 $773,010 - $1.14 Million
48,832 Added 4.55%
1,122,536 $23 Million
Q4 2023

Feb 07, 2024

BUY
$16.2 - $23.18 $6.38 Million - $9.12 Million
393,626 Added 57.88%
1,073,704 $23 Million
Q3 2023

Nov 02, 2023

SELL
$20.63 - $30.17 $132,320 - $193,510
-6,414 Reduced 0.93%
680,078 $14 Million
Q2 2023

Aug 07, 2023

BUY
$23.37 - $32.96 $4.62 Million - $6.51 Million
197,531 Added 40.4%
686,492 $20.3 Million
Q1 2023

May 09, 2023

SELL
$21.91 - $32.67 $821,581 - $1.23 Million
-37,498 Reduced 7.12%
488,961 $11.3 Million
Q4 2022

Feb 09, 2023

SELL
$26.28 - $33.92 $510,147 - $658,455
-19,412 Reduced 3.56%
526,459 $14.6 Million
Q3 2022

Nov 09, 2022

BUY
$25.97 - $38.53 $7.22 Million - $10.7 Million
278,139 Added 103.89%
545,871 $16.8 Million
Q2 2022

Aug 10, 2022

SELL
$20.88 - $35.19 $26,559 - $44,761
-1,272 Reduced 0.47%
267,732 $7.88 Million
Q1 2022

May 09, 2022

SELL
$29.0 - $47.27 $1.78 Million - $2.9 Million
-61,271 Reduced 18.55%
269,004 $8.65 Million
Q4 2021

Feb 09, 2022

BUY
$42.59 - $55.02 $1.13 Million - $1.46 Million
26,448 Added 8.7%
330,275 $14.7 Million
Q3 2021

Nov 09, 2021

SELL
$48.48 - $78.23 $1.24 Million - $2 Million
-25,517 Reduced 7.75%
303,827 $15.3 Million
Q2 2021

Aug 10, 2021

SELL
$50.3 - $78.44 $413,616 - $645,012
-8,223 Reduced 2.44%
329,344 $25.8 Million
Q1 2021

May 10, 2021

BUY
$53.8 - $81.53 $7 Million - $10.6 Million
130,063 Added 62.68%
337,567 $19.3 Million
Q4 2020

Feb 08, 2021

BUY
$36.89 - $93.56 $182,937 - $463,964
4,959 Added 2.45%
207,504 $17.4 Million
Q3 2020

Nov 06, 2020

BUY
$23.13 - $38.84 $12,096 - $20,313
523 Added 0.26%
202,545 $7.26 Million
Q2 2020

Aug 05, 2020

SELL
$16.01 - $28.82 $35,718 - $64,297
-2,231 Reduced 1.09%
202,022 $4.89 Million
Q1 2020

May 12, 2020

SELL
$14.2 - $27.98 $293,315 - $577,954
-20,656 Reduced 9.18%
204,253 $3.58 Million
Q4 2019

Feb 05, 2020

BUY
$14.4 - $19.99 $88,502 - $122,858
6,146 Added 2.81%
224,909 $3.92 Million
Q3 2019

Nov 13, 2019

SELL
$15.32 - $21.92 $20,743 - $29,679
-1,354 Reduced 0.62%
218,763 $3.35 Million
Q2 2019

Aug 12, 2019

BUY
$18.5 - $28.14 $617,104 - $938,665
33,357 Added 17.86%
220,117 $4.57 Million
Q1 2019

May 10, 2019

BUY
$17.99 - $24.65 $14,571 - $19,966
810 Added 0.44%
186,760 $4.34 Million
Q4 2018

Feb 14, 2019

SELL
$13.88 - $21.75 $235 - $369
-17 Reduced 0.01%
185,950 $3.84 Million
Q3 2018

Nov 14, 2018

BUY
$12.46 - $21.74 $40,457 - $70,589
3,247 Added 1.78%
185,967 $4.04 Million
Q2 2018

Aug 13, 2018

BUY
$15.25 - $21.02 $820,755 - $1.13 Million
53,820 Added 41.75%
182,720 $0
Q1 2018

May 14, 2018

SELL
$15.36 - $24.8 $796,707 - $1.29 Million
-51,869 Reduced 28.69%
128,900 $2.54 Million
Q4 2017

Feb 13, 2018

BUY
$15.04 - $21.45 $2.72 Million - $3.88 Million
180,769
180,769 $2.83 Million

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.31B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.